|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.965 USD | +5.45% |
|
+2.46% | -48.77% |
| 06-03 | Verastem Oncology Gets FDA Fast Track Designation for Lung Cancer Drug | DJ |
| 06-03 | Verastem's Lung Cancer Drug Gets FDA Fast Track Designation | MT |
| Market Cap | 330M 287M 264M 248M 463M 31.64B 472M 3.15B 1.22B 15.25B 1.24B 1.21B 53.02B | P/E Ratio 2026 * |
-2.41x | P/E Ratio 2027 * | -3.47x |
|---|---|---|---|---|---|
| Enterprise Value | 330M 287M 264M 248M 463M 31.64B 472M 3.15B 1.22B 15.25B 1.24B 1.21B 53.02B | EV / Sales 2026 * |
3.19x | EV / Sales 2027 * | 1.81x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Verastem, Inc.
| 1 day | +5.45% | ||
| 1 week | +2.46% | ||
| Current month | -8.66% | ||
| 1 month | -18.95% | ||
| 3 months | -36.11% | ||
| 6 months | -58.06% | ||
| Current year | -48.77% |
| 1 week | 3.55 |  | 4 |
| 1 month | 3.55 | | 5 |
| Current year | 3.55 | | 8.88 |
| 1 year | 3.55 | | 11.24 |
| 3 years | 2.1 | | 14.22 |
| 5 years | 2.1 | | 59.22 |
| 10 years | 2.1 | | 124.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 65 | 2023-07-31 |
Daniel Calkins
DFI | Director of Finance/CFO | 39 | 2022-10-30 |
John Hayslip
CTO | Chief Tech/Sci/R&D Officer | - | 2024-04-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Kauffman
CHM | Chairman | 62 | - |
Dan Paterson
BRD | Director/Board Member | 65 | 2023-07-31 |
Eric Rowinsky
BRD | Director/Board Member | 69 | 2017-05-02 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-20 | Free | Chairman | 36,000 | 0.0410% | ||
| 05-20 | Free | Director | 36,000 | 0.0410% | ||
| 05-20 | Free | Director | 36,000 | 0.0410% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.45% | +2.46% | -33.75% | -60.01% | 330M | |
| +1.65% | +6.42% | +53.16% | +109.62% | 54.82B | |
| +0.03% | -1.80% | +49.57% | +43.94% | 43.27B | |
| +4.20% | -0.92% | -15.83% | -19.15% | 21.79B | |
| +6.18% | -7.22% | -0.65% | +399.18% | 19.92B | |
| +0.81% | -8.38% | +12.77% | -33.24% | 15.67B | |
| +0.53% | +2.08% | +8.89% | -40.13% | 15.26B | |
| +2.42% | +2.46% | +29.81% | +181.72% | 13.22B | |
| -5.27% | +3.89% | +90.88% | +208.02% | 11.58B | |
| -1.74% | -1.05% | +12.88% | - | 11.94B | |
| Average | +1.42% | -0.13% | +20.77% | +87.77% | 20.78B | |
| Weighted average by Cap. | +1.34% | +1.16% | +31.89% | +97.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 103M 89.81M 82.79M 77.57M 145M 9.91B 148M 988M 382M 4.78B 389M 380M 16.61B | 183M 159M 146M 137M 256M 17.5B 261M 1.74B 675M 8.44B 686M 671M 29.33B |
| Net income | -164M -142M -131M -123M -229M -15.68B -234M -1.56B -605M -7.56B -615M -602M -26.28B | -137M -119M -109M -102M -191M -13.09B -195M -1.3B -505M -6.31B -513M -502M -21.93B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-11 | 3.950 $ | +5.05% | 1,101,761 |
| 26-06-10 | 3.760 $ | -1.57% | 2,221,212 |
| 26-06-09 | 3.820 $ | +4.09% | 3,069,755 |
| 26-06-08 | 3.670 $ | -1.08% | 1,866,569 |
| 26-06-05 | 3.710 $ | -3.89% | 3,046,993 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VSTM Stock
Select your edition
All financial news and data tailored to specific country editions
